WELL Health Technologies will reward investors, Haywood says

Clinical operations continue to trend attractively for Well Health Technologies (Well Health Technologies Stock Quote, Chart TSXV:WELL), according to Haywood Capital Markets analyst Daniel Rosenberg, who in a client update on Thursday says that the stock remains undervalued.

Healthcare clinic and health tech company Well Health reported its first quarter ended March 31, 2019, financials on Wednesday, featuring revenue of $7.4 million, an upgrade from Q1 of 2018’s $1.9 million and better than analysts’ consensus at $6.8 million. That came with an EBITDA loss of $0.3 million as the company remains in the early days of establishing its operations and services.

Well Health grew by 13 clinics over 2018 and acquired EMR provider NerdEMR in January. While the company’s revenue mix is still largely comprised of its insured services, with technology revenue only accounting for two per cent of total revenue, Rosenberg says he expects new initiatives within clinics and the acquisition of OSCARprn, announced on May 23, to add incremental revenue for the year and help improve margins.

“WELL is in the early days of leveraging technology to improve outcomes and drive operational efficiencies in the ripe healthcare sector. Predictable cash flows from the primary health clinics help to de-risk WELL’s strategy of incubating, deploying and scaling new technologies in healthcare. We like this strategy and believe investors will be rewarded as WELL unlocks synergies between primary clinics, patients and technology solutions,” says Rosenberg.

The analyst has made minor adjustments to his forecast and is calling for 2019 revenue and Adjusted EBITDA of $29.0 million and negative $1.2 million, respectively, and 2020 revenue and Adjusted EBITDA of $37.8 million and $0.5 million, respectively.

Rosenberg is maintaining his “Buy” rating and $0.90 target, which represents a projected return of 29 per cent at the time of publication.

Disclosure: Cantech’s Nick Waddell owns shares of WELL and the company is an annual sponsor of Cantech Letter.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: well
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Silicon Motion stock still a buy, Roth says

Following the company's first quarter results, Roth MKM analyst Suji Desilava remains bullish on Silicon Motion Technology (Silicon Motion Technology… [Read More]

26 mins ago

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

3 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

4 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

4 days ago